You are here
Panzem Formulation Undergoing Phase I Testing
ROCKVILLE, Md., March 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage biopharmaceutical company developing therapeutics primarily for the treatment of cancer, today announced that a new formulation of Panzem®, the Company's lead clinical drug candidate, is currently being evaluated in a Phase I clinical trial. This formulation is being administered in various oral forms. The objectives of the trial in healthy human volunteers are to determine the pharmacokinetics and safety profiles of these dosage forms.
Neil Campbell, EntreMed President and Chief Operating Officer, commented, "Our work with the new Panzem® formulation remains on schedule as we take the next step in the project by assessing these dosage forms in healthy volunteers."
Panzem® (2-Methoxyestradiol, 2ME2) has been administered to more than 160 advanced cancer patients to date and has exhibited a strong safety profile. Panzem® has been tested in cancer patients as a single agent, as well as in combination with chemotherapeutics. Clinicians have reported signs of clinical benefit in patients with advanced cancer, including a complete response and a few partial responses, as well as stable disease.
Source: EntreMed, Inc.